Oshima, Megumi

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE Trial

Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 176

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 166

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial

Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 142

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology

Erythropoietin and Anemia TreatmentDiabetes Treatment and Management

Cited by 135

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 115

Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial

Heerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 56

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients

Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews

Diabetes Treatment and ManagementRenal Transplantation Outcomes and Treatments

Cited by 30